Name | Title | Contact Details |
---|
Alkeus Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing transformative therapeutics to address serious, progressive eye diseases that lead to blindness. Our lead compound, ALK-001, is an oral investigational drug being developed for the treatment of Stargardt disease (STGD) and Geographic Atrophy (GA) secondary to dry age-related macular degeneration. ALK-001 is a selectively-deuterated form of Vitamin A that slows the dimerization of Vitamin A, which is implicated in STGD, and has shown statistically-significant and clinically-meaningful efficacy in the TEASE-1 Phase 2 clinical trial. Based on these results, ALK-001 has been granted Breakthrough Therapy Designation for the treatment of Stargardt Disease.
Document Concepts is a Canton, OH-based company in the Business Services sector.
Psyop is a multi-disciplinary studio specializing in emotive, visually stunning storytelling for the advertising, video gaming, broadcast and music video industries.
Tapco Underwriters Inc is a Burlington, NC-based company in the Business Services sector.
Otaku eZine is a Calgary, AB-based company in the Business Services sector.